Chemoprophylaxis of COVID-19 with hydroxychloroquine - a study of health care workers attitude, adherence to regime and side effects

Author:

Bhattacharyya Debajyoti,Raizada Neeraj,Nagappa Bharathnag,Tomar Arvind,Maurya Prateek,Chaudhary Ashok,George Mini,Katiyal Deepty,Rajora Srishti,Singh Nikky

Abstract

AbstractBackgroundThere are apprehensions amongst healthcare worker (HCWs) about COVID-19. The HCWs have been given hydroxychloroquine (HCQ) chemoprophylaxis for seven weeks as per Government of India guidelines.ObjectivesTo assess the apprehensions amongst HCWs about COVID-19 and to document accessibility, adherence and side effects related to HCQ prophylaxis in HCWs.MethodsA longitudinal follow up study was conducted in a tertiary care hospital. HCQ was given in the dose of 400 mg twice on day one, and then 400 mg weekly for seven weeks. 391 HCWs were interviewed using semi structured questionnaire.Results62.2% HCWs expressed perceived danger posted by COVID-19 infection. Doctors (54%) showed least acceptance and paramedics (88%) showed highest acceptance to chemoprophylaxis. 17.5% participants developed at least one of the side effects to HCQ. Females and nursing profession were significantly associated with adverse effects. Common side effects were gastro-intestinal symptoms, headache and abnormal mood change. Most of these were mild, not requiring any intervention. Gender, professions and perceived threat of COVID-19 were significantly associated with acceptance and adherence to HCQ prophylaxis.ConclusionTwo third of HCWs had perceived danger due to COVID-19. Three fourth of the HCWs accepted chemoprophylaxis and four out of five who accepted had complete adherence to prophylaxis schedule. One out of five had developed at least one of side effects; however, most of these were mild not requiring any intervention.

Publisher

Cold Spring Harbor Laboratory

Reference30 articles.

1. Cascella M , Rajnik M , Cuomo A , Dulebohn SC , Di Napoli R. Features, Evaluation and Treatment Coronavirus (COVID-19). StatPearls. 2020.http://www.ncbi.nlm.nih.gov/pubmed/32150360 (Accessed on 28 May 2020)

2. Clinical Characteristics of Coronavirus Disease 2019 in China

3. Updated Approaches against SARS-CoV-2

4. NCT04304053. Treatment of Mild Cases and Chemoprophylaxis of Contacts as Prevention of the COVID-19 Epidemic. https://clinicaltrials.gov/show/NCT04304053. 2020; (Accessed on 28 May 2020)

5. Division of Viral Diseases - National Center for Immunization and Respiratory Diseases. Therapeutic Options for COVID-19 Patients. Centers for Disease Control and Prevention. 2020.www.cdc.gov/coronavirus/2019-ncov/hcp/therapeutic-options.html (Accessed on 28 May 2020)

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3